Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

Gabriel Bsteh; Harald Hegen; Katharina A. Riedl; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Rainer Ehling; Barbara Kornek; Tobias Monschein; Walter Rinner; Christiane Schmied; Sebastian Wurth; Karin Zebenholzer; Anne Zinganell; Tobias Zrzavy; Gudrun Zulehner; Florian Deisenhammer; Paulus Rommer; Fritz Leutmezer; Thomas Berger

doi:10.1111/ene.14705

Abstract

The composite VIAADISC score is a valuable tool to inform and support patients and neurologists in the process of decision making to discontinue injectable DMTs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bsteh et al. (2020) studied this question.

synapsesocial.com/papers/69d9aa239a6164e50fa3d370 https://doi.org/10.1111/ene.14705

View Full Paper

Ask AI

Bookmark

Share

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

Abstract

Discussion

Cite This Study

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Journal of Neurology

Keep reading

More related papers

More from European Journal of Neurology